Expression of estrogen receptor and progesterone receptor in endometrial cancer and their correlations with clinicopathological features.
- 1Department of Obstetrics and Gynecology, Kiang Wu Hospital, Macau SAR, China.
- 2Department of Pathology, Kiang Wu Hospital, Macau SAR, China.
Abstract
Objective
To investigate the expression levels of estrogen receptor (ER) and progesterone receptor (PR) in endometrial carcinoma (EC) and their correlations with standardized clinicopathological parameters in a single-center surgical cohort.Methods
Retrospective clinical and pathological data of 78 EC patients receiving primary surgery at the Department of Obstetrics and Gynecology of Kiang Wu Hospital between Jan 2016 and Aug 2022 were collected. ER/PR expression was quantified via immunohistochemistry (IHC) using the Allred scoring system. Dichotomous receptor positivity (Allred 0-2 negative/3-8 positive) and continuous total Allred scores were analyzed separately. Fisher's exact test or χ² test was used for categorical comparison; Kruskal-Wallis H test with adjusted post-hoc pairwise tests and Wilcoxon rank-sum test were applied for ordinal Allred score data. Exact P values, test statistics and degrees of freedom were reported for all analyses.Results
The overall cohort included 71 endometrioid carcinoma (EC) and 7 non-endometrioid carcinoma (NEC) cases. ER and PR positive rates were significantly higher in endometrioid lesions (97.2% and 94.4%) than non-endometrioid subtypes (57.1% for both, P = 0.018/P = 0.018). Continuous Allred scores of ER and PR declined significantly with worsening tumor differentiation (all adjusted P<0.05). For FIGO staging, significantly reduced ER and PR Allred scores were observed in Stage II compared with Stage I. The single Stage-III case was reported descriptively and was not included in formal statistical testing. Patients with lymph node metastasis exhibited lower PR Allred scores (P = 0.021), while ER expression showed no statistically significant difference (P = 0.076). No significant associations were found between ER/PR scores and depth of myometrial invasion or lymphovascular space invasion (LVSI) (all P>0.05).Conclusion
Reduced ER and PR expression correlates with poorer tumor differentiation and advanced FIGO stage in endometrioid endometrial carcinoma; PR loss is independently associated with lymph node metastasis. This study only identifies crude cross-sectional correlations without survival or multivariable adjustment data, so ER/PR may merely serve as auxiliary morphological markers reflecting tumor aggressive potential, rather than standalone indicators for prognosis or individualized hormone therapy guidance.
Related
- Association of VCP/p97 Expression with Clinicopathological Features and Overall Survival in Endometrioid Endometrial Carcinoma
- Prognostic Significance of B7-H3, TROP2, and p16 Expression in Pleural Mesothelioma: Clinicopathological Correlations and Survival Outcomes
- A nomogram integrating YTHDC2 expression and clinicopathological parameters for predicting endometrial cancer recurrence: a multicenter retrospective study
- Progesterone Beyond Pituitary Suppression in Assisted Reproduction: Peripheral Signalling, Gamete Biology, Endometrial Competence and Precision Therapeutic Use
- Progesterone receptor variants and hormone therapy use in postmenopausal endometrial polyps: a case-control study.
BibTeX
@article{li2026expression,
title = {{Expression of estrogen receptor and progesterone receptor in endometrial cancer and their correlations with clinicopathological features.}},
author = {En Ping Li and Yu Hong and Jie Zhen Wei and Chun Ke Li and Hai Qi Liang},
journal = {Frontiers in oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1939245},
url = {https://europepmc.org/article/MED/42903215},
note = {CC BY},
}
RIS
TY - JOUR
TI - Expression of estrogen receptor and progesterone receptor in endometrial cancer and their correlations with clinicopathological features.
AU - En Ping Li
AU - Yu Hong
AU - Jie Zhen Wei
AU - Chun Ke Li
AU - Hai Qi Liang
PY - 2026
DA - 2026/10/06
JO - Frontiers in oncology
DO - 10.3389/fonc.2026.1939245
UR - https://europepmc.org/article/MED/42903215
AB - Objective To investigate the expression levels of estrogen receptor (ER) and progesterone receptor (PR) in endometrial carcinoma (EC) and their correlations with standardized clinicopathological parameters in a single-center surgical cohort.Methods Retrospective clinical and pathological data of 78 EC patients receiving primary surgery at the Department of Obstetrics and Gynecology of Kiang Wu Hospital between Jan 2016 and Aug 2022 were collected. ER/PR expression was quantified via immunohistochemistry (IHC) using the Allred scoring system. Dichotomous receptor positivity (Allred 0-2 negative/3-8 positive) and continuous total Allred scores were analyzed separately. Fisher's exact test or χ² test was used for categorical comparison; Kruskal-Wallis H test with adjusted post-hoc pairwise tests and Wilcoxon rank-sum test were applied for ordinal Allred score data. Exact P values, test statistics and degrees of freedom were reported for all analyses.Results The overall cohort included 71 endometrioid carcinoma (EC) and 7 non-endometrioid carcinoma (NEC) cases. ER and PR positive rates were significantly higher in endometrioid lesions (97.2% and 94.4%) than non-endometrioid subtypes (57.1% for both, P = 0.018/P = 0.018). Continuous Allred scores of ER and PR declined significantly with worsening tumor differentiation (all adjusted P<0.05). For FIGO staging, significantly reduced ER and PR Allred scores were observed in Stage II compared with Stage I. The single Stage-III case was reported descriptively and was not included in formal statistical testing. Patients with lymph node metastasis exhibited lower PR Allred scores (P = 0.021), while ER expression showed no statistically significant difference (P = 0.076). No significant associations were found between ER/PR scores and depth of myometrial invasion or lymphovascular space invasion (LVSI) (all P>0.05).Conclusion Reduced ER and PR expression correlates with poorer tumor differentiation and advanced FIGO stage in endometrioid endometrial carcinoma; PR loss is independently associated with lymph node metastasis. This study only identifies crude cross-sectional correlations without survival or multivariable adjustment data, so ER/PR may merely serve as auxiliary morphological markers reflecting tumor aggressive potential, rather than standalone indicators for prognosis or individualized hormone therapy guidance.
SN - 2234-943X
ER -